Overview

Safety and Tolerability of Varenicline in Schizophrenia (SATOVA)

Status:
Withdrawn
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a 15 week trial to determine (1) the safety and tolerability of varenicline when used for smoking cessation/reduction in individuals with schizophrenia; (2) if treatment with varenicline affects the symptoms of schizophrenia.
Phase:
Phase 4
Details
Lead Sponsor:
University of British Columbia
Collaborator:
Provincial Health Services Authority
Treatments:
Varenicline